Lakewood-Amedex announces 1-for-10 reverse stock split effective June 19, 2026

Lakewood-Amedex Biotherapeutics Inc.

Reverse split ratio: 1-for-10; effective at 4:01 p.m. ET on June 19, 2026; trading starts split-adjusted on Nasdaq June 22.
Outstanding shares reduced from ~17,506,577 to ~1,750,789; fractional shares rounded up to next whole share.
Authorized shares reduced proportionately to 12,500,000; new CUSIP 51255A201 assigned; ticker LABT unchanged.
Board unanimously approved the split on June 1, 2026; adjustments made to equity awards, warrants, and preferred stock.
No stated reason for the split; typical use is to regain Nasdaq minimum bid price compliance.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lakewood-Amedex Biotherapeutics Inc.: Filed a Certificate of Change to effectuate a 1-for-10 reverse stock split and reduce authorized shares to 12,500,000 (effective 2026-06-19).

Change: charter amendment
Effective: 2026-06-19

Exact text from the filing

On June 15, 2026, Lakewood-Amedex Biotherapeutics Inc (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”).

View on SEC.gov

255 governance changes filed in the last 30 days. Browse all governance changes →

Lakewood-Amedex Biotherapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-069512

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.